Skip to main content

Table 1 Characteristics of 162 smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with TPF

From: Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil

Age   
  Median 53
  Mean 52.4
  Range 31–72
Sex   
  Male 156 (96 %)
  Female 6 (4 %)
Primary tumor site   
  Hypopharynx 19 (12 %)
  Larynx 17 (10 %)
  Oropharynx 60 (37 %)
  Oral cavity 62 (38 %)
  Unknown primary 4 (3 %)
Clinical T classification   
  T1 4 (3 %)
  T2 23 (14 %)
  T3 12 (7 %)
  T4a 49 (30 %)
  T4b 70 (43 %)
  Tx 4 (3 %)
Clinical N classification   
  N0 28 (18 %)
  N1 20 (12 %)
  N2a 7 (4 %)
  N2b 49 (30 %)
  N2c 41 (25 %)
  N3 17 (11 %)
Clinical 7th AJCC stage   
  IVA 80 (49 %)
  IVB 82 (51 %)
Alcohol   
  Absent 16 (10 %)
  Present 146 (90 %)
Betel nut chewing   
  Absent 31 (19 %)
  Present 131 (81 %)
p16 expression   
  Negative 128 (79 %)
  Positive 3 (2 %)
  Unknown 31 (19 %)
Response to induction chemotherapy   
  Complete response 9 (6 %)
  Partial response 90 (55 %)
  Stable disease 42 (26 %)
  Progression disease 21 (13 %)
  1. TPF docetaxel, cisplatin, and fluorouracil